Genertec Meheco to Distribute Pfizer Inc.'s COVID-19 Treatment Paxlovid on Chinese Mainland

An agreement was signed on March 9 by which China Meheco International Co., Ltd., a subsidiary of China General Technology (Group) Holding Co., Ltd. (Genertec), will be responsible for supplying of Pfizer Inc.'s COVID-19 treatment Paxlovid on the Chinese mainland in 2022.

Paxlovid has previously obtained conditional approval from the National Medical Products Administration, China's top drug regulator.

The small molecule COVID-19 treatment drug can be used to treat adults who have mild to moderate symptoms and those having high risks of progressing to more severe disease like chronic kidney or lung issues, cardiovascular disease, diabetes or other high-risk factors.

(Executive editor: Niu Yilin)